MabPlex

Yantai, China Founded: 2013 • Age: 13 yrs
Biologics development and GMP manufacturing services are offered.
Request Access

About MabPlex

MabPlex is a company based in Yantai (China) founded in 2013.. MabPlex has raised $130 million across 2 funding rounds from investors including Orbimed, Sunshine Insurance Group and Detong Capital. MabPlex offers products and services including CDMO Services, Research Development, and GMP Manufacturing. MabPlex operates in a competitive market with competitors including Bionova Scientific, Just Biotherapeutics, JHL Biotech, Avid Bioservices and ProBioGen AG, among others.

  • Headquarter Yantai, China
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Mabplex International Co. Ltd.
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $130 M (USD)

    in 2 rounds

  • Latest Funding Round
    $71 M (USD), Series B

    Jun 08, 2020

  • Investors
    Orbimed

    & 9 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of MabPlex

MabPlex offers a comprehensive portfolio of products and services, including CDMO Services, Research Development, and GMP Manufacturing. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Offers contract services for biologics research and production

Provides development support for biopharmaceutical innovations

Delivers compliant manufacturing for biologics and ADCs

Funding Insights of MabPlex

MabPlex has successfully raised a total of $130M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $71 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series B — $71.0M
  • First Round

    (21 Jan 2019)

  • Investors Count 10
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2020 Amount Series B - MabPlex Valuation Detong Capital , Huajin Capital
Jan, 2019 Amount Series A - MabPlex Valuation Shenzhen Capital Group , SDIC Venture Capital Management
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in MabPlex

MabPlex has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Sunshine Insurance Group and Detong Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by MabPlex

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - MabPlex

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Mabplex Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of MabPlex

MabPlex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bionova Scientific, Just Biotherapeutics, JHL Biotech, Avid Bioservices and ProBioGen AG, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Mammalian cell culture biologics are developed through contract research services.
domain founded_year HQ Location
Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs
domain founded_year HQ Location
Contract manufacturing solutions for biologics are provided to Asian companies.
domain founded_year HQ Location
Drug substance development, analytical, and compliance services are provided.
domain founded_year HQ Location
Contract development and manufacturing organization focussed on therapeutic proteins/antibodies, viral vaccines and biosimilars
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Mabplex

Frequently Asked Questions about MabPlex

When was MabPlex founded?

MabPlex was founded in 2013 and raised its 1st funding round 6 years after it was founded.

Where is MabPlex located?

MabPlex is headquartered in Yantai, China. It is registered at Yantai, Shandong, China.

Is MabPlex a funded company?

MabPlex is a funded company, having raised a total of $130M across 2 funding rounds to date. The company's 1st funding round was a Series A of $59M, raised on Jan 21, 2019.

What does MabPlex do?

MabPlex was established in 2013 as a contract development and manufacturing organization based in Yantai, China. Focus is placed on biologics, including antibody-drug conjugates, mammalian cell-line derived active pharmaceutical ingredients, and monoclonal antibodies. Services encompass cell banking, protein characterization, formulation, lyophilization, fill-finish operations, and final packaging. Quality assurance, control, and regulatory support are provided, with compliance to FDA, EMA, and CFDA standards maintained.

Who are the top competitors of MabPlex?

MabPlex's top competitors include Avid Bioservices, Bionova Scientific and Rentschler Biopharma.

What products or services does MabPlex offer?

MabPlex offers CDMO Services, Research Development, and GMP Manufacturing.

Who are MabPlex's investors?

MabPlex has 10 investors. Key investors include Orbimed, Sunshine Insurance Group, Detong Capital, CMS China, and Huayao Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available